A study to evaluate the effect of the experimental drug abelacimab relative to placebo in subjects with atrial fibrillation/flutter (AF) who are not treated with oral anticoagulants because they have been deemed by their responsible physicians or by their own decision to be unsuitable for currently available oral blood thinners.
Contact phone
517. 364. 5760
Contact email
scri@sparrow.org
Principal investigator
Dr. John Ip, MD, FACC
Trial Category
Heart & Vascular
Trial SubCategory
Atrial Fibrillation
Webform